P21 vs GB-115
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: P021, Ac-DGGLAG-NH2
A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
Also: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- GB-115 has stronger research evidence (Human Trials) compared to P21 (Animal Studies).
Detailed Comparison
| Attribute | P21 | GB-115 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | P21 acts as a CNTF small-molecule peptide mimetic. It enhances neurogenesis in the hippocampus, reduces tau phosphorylation, inhibits neuroinflammation, and improves synaptic plasticity. Designed to be orally bioavailable. | GB-115 works by blocking central cholecystokinin-1 (CCK-1) receptors in the brain. CCK is involved in anxiety, panic responses, and cognitive modulation. By antagonizing these receptors, GB-115 reduces anxiety while improving attention, processing speed, and reaction time. It also modulates dopaminergic pathways involved in focus and motivation. |
| Common Dosing | Limited community data available See research protocols | 6 mg daily (2 mg three times daily) 2-3 times daily (morning, afternoon, evening) |
| Administration | Oral (nasal in some studies) | Oral tablets or sublingual |
| Typical Duration | Ongoing supplementation in studies | 21+ days in clinical trials, effects noted by day 7 |
| Best Time to Take | Morning | Morning and throughout the day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show cognitive improvement in Alzheimer's mouse models. Research demonstrates increased neurogenesis, reduced tau pathology, and improved learning/memory. Being developed for Alzheimer's and age-related cognitive decline. | Clinical studies in patients with Generalized Anxiety Disorder (GAD) showed GB-115 (6mg/day) significantly improved reaction time, attention, and processing speed within 7 days of treatment. A 21-day trial with 31 patients demonstrated anxiolytic effects comparable to benzodiazepines without sedation or dependency. Currently in Phase II/III trials (NCT05586789) for anxiety disorders. Anecdotal reports suggest benefits for ADHD symptoms, though direct ADHD trials are pending. |
Frequently Asked Questions: P21 vs GB-115
What is the difference between P21 and GB-115?
P21 is a cognitive peptide that a synthetic peptide mimetic of cntf (ciliary neurotrophic factor) designed for neurodegenerative disease. promotes neurogenesis and reduces neuroinflammation. GB-115 is a cognitive peptide that a dipeptide anxiolytic and nootropic that acts as a cck-1 (cholecystokinin) receptor antagonist. developed in russia with completed phase 3 trials for anxiety. users report significant improvements in focus, attention, and adhd-like symptoms. The main differences lie in their mechanisms of action and clinical applications.
Which is better, P21 or GB-115?
Neither is universally "better" - the choice depends on your specific goals. P21 is typically used for cognitive purposes, while GB-115 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can P21 and GB-115 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using P21 and GB-115 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.